Exelixis
EXEL
#1812
Rank
A$15.66 B
Marketcap
A$58.43
Share price
-1.39%
Change (1 day)
-0.62%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): A$3.63

According to Exelixis's latest financial reports the company's current EPS (TTM) is A$3.38. In 2023 the company made an earnings per share (EPS) of A$0.93 an increase over its 2022 EPS that were of A$0.81.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$3.63
2023A$0.9314.61%
2022A$0.81-22.97%
2021A$1.05100%
2020A$0.53-65.09%
2019A$1.50-53.91%
2018A$3.26333.96%
2017A$0.75-260.61%
2016A-$0.47-58.75%
2015A-$1.14-42.45%
2014A-$1.975.3%
2013A-$1.87

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
A$15.81 367.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$1.93-42.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$20.34 502.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$2.93-13.23%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$10.37 207.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$4.22 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$5.35 58.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
A-$5.21-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
A-$1.19-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA